The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to provide a more substantial reduction in body weight and benefit metabolic health, particularly conc